Clinical Trials Browser

Phase 2 × Vipoma × NET × Clear all

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Phase 2 Withdrawn

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

NCT00050349 2017-03-01

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Phase 2 Completed

33 enrolled

EndocrineNET

Carcinoid Tumor, Carcinoma, Vipoma, Neoplasm Metastasis, Neoplasms, Gastrinoma, Neuroendocrine Tumors

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Phase 2 Completed

41 enrolled 9 charts

EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Clinical Trials

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Capecitabine and Temozolomide for Neuroendocrine Cancers